LONDON, UK, 7 November 2006 -- SkyePharma PLC (Nasdaq: SKYE; LSE: SKP) notes that Abbott yesterday announced the acquisition of Kos Pharmaceuticals, Inc. Kos has the exclusive licence to jointly develop Flutiform™, SkyePharma’s novel combination product for asthma and chronic obstructive pulmonary disease (“COPD”).
